Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers

2021 ◽  
pp. 163-181
Author(s):  
Huseyin Beyaz ◽  
Hasan Uludag ◽  
Doga Kavaz ◽  
Nahit Rizaner
Keyword(s):  
Drug Resistance ◽  
Breast Cancers ◽  
Nanoparticle Delivery

Nanoparticle delivery systems to combat drug resistance in ovarian cancer

2021 ◽  
Vol 31 ◽  
pp. 102309
Author(s):  
Emily M. Miller ◽  
Timothy M. Samec ◽  
Angela A. Alexander-Bryant
Keyword(s):  
Ovarian Cancer ◽  
Drug Resistance ◽  
Delivery Systems ◽  
Nanoparticle Delivery

Biopsy-driven study to identify biomarkers of drug resistance in patients with triple-negative breast cancer.

2012 ◽  
Vol 30 (30_suppl) ◽  
pp. 87-87
Author(s):  
Adriana Aguilar-Mahecha ◽  
Josiane Lafleur ◽  
Elaheh Ahmadzadeh ◽  
Ewa Przybytkowski ◽  
Carole Seguin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Cell Lines ◽  
Triple Negative ◽  
Acquired Resistance ◽  
Great Difficulty ◽  
Clinical Samples ◽  
Drug Resistant ◽  
Breast Cancers ◽  
Breast Cancer Patients

87 Background: Resistance to chemotherapy is the underlying cause of death in most patients dying of breast cancer. Patients with early stages of breast cancer whose tumor is or becomes resistant to chemotherapy have a poor prognosis, while women with advanced breast cancer live as long as their tumors respond to chemotherapy. Because of the great difficulty of obtaining clinical samples from drug resistant tumors in patients, there is scant information about molecular factors from actual drug resistant tumors. This project aims to systematically profile resistant triple negative breast cancers (TNBCs) in order to discover molecular “resistance” genes/proteins as a first step to develop strategies to overcome drug resistance. Methods: Paired biopsies are collected from TNBC patients (NCT01276899). Four needle core biopsies are collected before the initiation of treatment and 2 weeks before surgery or at the time of progression in the neoadjuvant and metastatic settings respectively. Paired biopsies will undergo Next Gen Sequencing, flow sorted aCGH analysis, gene expression and miRNA profiling as well as phosphoproteomic profiling using reverse phase protein arrays. Results: We have currently enrolled 28 patients in the neoadjuvant setting and 3 metastatic patients. We have standardized the methods of collection and processing of tissue and blood specimens to ensure their molecular integrity and compatibility with different genomic and proteomic molecular platforms. Analysis of tumor cellularity has been incorporated into our quality control and we have optimized the extraction of nucleic acids to obtain high yields and optimal quality. In parallel, we have generated acquired resistance to paclitaxel in a panel of TNBC cell lines. These cell lines will also undergo genomic profiling and exome sequencing to identify molecular markers of resistance that will be correlated with the markers found in patient samples. Conclusions: This project will allow us to identify the molecular factors responsible for drug resistance in TNBCs and enable the elaboration of strategies to overcome resistance.

scholarly journals Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

2012 ◽  
Vol 18 (7) ◽  
pp. 1052-1059 ◽  
Author(s):  
Justin M Balko ◽  
Rebecca S Cook ◽  
David B Vaught ◽  
María G Kuba ◽  
Todd W Miller ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Neoadjuvant Chemotherapy ◽  
Breast Cancers

Hypoxia-mediated drug resistance in breast cancers

2020 ◽  
Author(s):  
Courtney E. McAleese ◽  
Chandra Choudhury ◽  
Neville J. Butcher ◽  
Rodney F. Minchin
Keyword(s):  
Drug Resistance ◽  
Breast Cancers

Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models

2017 ◽  
Vol 13 (3) ◽  
pp. 965-976 ◽  
Author(s):  
Cai M. Roberts ◽  
Sophia Allaf Shahin ◽  
Wei Wen ◽  
James B. Finlay ◽  
Juyao Dong ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Resistance ◽  
Tumor Growth ◽  
Nanoparticle Delivery ◽  
Cancer Models

scholarly journals Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins

2005 ◽  
Vol 12 (4) ◽  
pp. 999-1009 ◽  
Author(s):  
Jörg B Engel ◽  
Andrew V Schally ◽  
Gabor Halmos ◽  
Benjamin Baker ◽  
Attila Nagy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Cell Lines ◽  
Antitumor Effect ◽  
Multi Drug Resistance ◽  
Breast Cancers ◽  
Human Breast ◽  
Resistance Protein ◽  
Grp Receptors ◽  
Mdr 1

The cytotoxic analog of bombesin (BN)/gastrin releasing peptide (GRP) AN-215 consisting of 2-pyrrolinodoxorubicin (AN-201), a superactive derivative of doxorubicin linked to a bombesin analog carrier, displays a high affinity to BN/GRP receptors and can be targeted to tumors that express these receptors. We evaluated the antitumor effect and the toxicity of AN-215 in 5 human breast cancer cell lines xenografted into nude mice. In addition, we measured the mRNA expression of multi drug resistance protein 1 (MDR-1), multi drug resistance related protein 1 (MRP-1) and breast cancer resistance protein (BCRP) by real-time PCR analysis after treatment with AN-215. All five cell lines expressed BN/GRP receptors, and AN-215 significantly (P<0.05) inhibited tumor growth in all models, while its cytotoxic radical AN-201 had no significant effect in four models. In MX-1 tumors, AN-201 had a significantly weaker antitumor effect than AN-215. The effect of AN-215 was nullified by a blockade of BN/GRP receptors with a bombesin antagonist. Low or no induction of MDR-1, MRP-1 and BCRP occurred after treatment with AN-215. In conclusion, targeted chemotherapy with the cytotoxic BN/GRP analog AN-215 strongly inhibits breast cancers that express BN/GRP receptors and might provide a new treatment modality for mammary carcinoma.

scholarly journals ABL1-dependent OTULIN phosphorylation promotes genotoxic Wnt/β-catenin activation to enhance drug resistance in breast cancers

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Wei Wang ◽  
Mingqi Li ◽  
Suriyan Ponnusamy ◽  
Yayun Chi ◽  
Jingyan Xue ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Breast Cancers
Sign in / Sign up

Export Citation Format

Share Document